Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: A pilot study

Nephrology Dialysis Transplantation

Volumn 23, Issue 1, 2008, Pages 369-373

  Türk, Tobias R ^a   Voropaeva, Eva ^a   Kohnle, Matthias ^a   Nürnberger, Jens ^a   Philipp, Thomas ^a   Kribben, Andreas ^a   Heemann, Uwe ^b   Witzke, Oliver ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Allograft function; Ezetimibe; Hypercholesterolemia; Renal transplantation

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CREATININE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ALLOGRAFT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; CASE CONTROL STUDY; CLINICAL TRIAL; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 44449096625     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm620     Document Type: Article

References (21)

1. Masterson R, Hewitson T, Leikis M, Walker R, Cohney S, Becker G. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 2005; 80: 332-338
2. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation: the effects of statins. Am J Kidney Dis 2002; 40: 638-643
3. Ruiz MC, Moreno JM, Ruiz N, Vargas F, Asensio C, Osuna A. Effect of statin treatment on oxidative stress and renal function in renal transplantation. Transplant Proc 2004; 38: 2431-2433
4. Steiner S, Winkelmayer WC, Kleinert J et al. Endothelial progenitor cells in kidney transplant recipients. Transplantation 2006; 81: 599-606
5. Puthenparumbil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005; 37: 1033-1035
6. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006; 81: 804-807
7. Kohnle M, Pietruck F, Kribben A, Philipp Th, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006; 6: 205-208
8. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006; 6: 770-774
9. Kasiske B, Cosio FG, Beto J et al. National Kidney Foundation Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4: 13-53
10. Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-391
11. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497
12. Witzke O, Schmidt C, Kohnle M, Lütkes P, Philipp Th, Heemann U. Impact of febrile infections on the long-term function of kidney allografts. J Urol 2001; 166: 2048-2052
13. Poge U, Gerhardt T, Palmedo H et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5: 1306-1311
14. Dimeny E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellstrom B. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993; 23: 572-579
15. Isoniemi H, Nurminen M, Tikkanen MJ et al. Risk factors predicting chronic rejection of renal allografts. Tranplantation 1994; 57: 68-72
16. Hamar P, Müller V, Kohnle M et al. Metabolic factors have a major impact on kidney allograft survival. Transplantation 1997; 64: 1135-1139
17. Roodnat JI, Mulder PGH, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 1704-1710
18. Fellström B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C. The Assessment of Lescol in Renal Transplantation (ALERT) study group. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clin Transplant 2006; 20: 732-739
19. Asberg A, Hartmann A, Fjeldsa E, Holdaas H. Atorvastatin improves endothelial function of in renal transplant recipients. Nephrol Dial Transplant 2001; 19: 1920-1924
20. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mugge A, Spieker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome - effect of different lipid-lowering regimens. Cardiology 2006; 105: 139-140
21. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006; 10: 851-866